Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 24-week results from a randomized controlled trial

Diabetes Care

Volumn 41, Issue 9, 2018, Pages 1938-1946

  Mathieu, Chantal ^a   Dandona, Paresh ^b   Gillard, Pieter ^a   Senior, Peter ^c   Hasslacher, Christoph ^d   Araki, Eiichi ^e   Lind, Marcus ^f,g   Bain, Stephen C ^h   Jabbour, Serge ⁱ   Arya, Niki ^j   Hansen, Lars ^k   Thorén, Fredrik ^l   Langkilde, Anna Maria ^l  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY AT BUFFALO   (United States)

^c UNIVERSITY OF ALBERTA   (Canada)

^d Diabetesinstitut Heidelberg   (Germany)

^e KUMAMOTO UNIVERSITY   (Japan)

^f UNIVERSITY OF GOTHENBURG   (Sweden)

^g NU Hospital Organization   (Sweden)

^h SWANSEA UNIVERSITY   (United Kingdom)

ⁱ THOMAS JEFFERSON UNIVERSITY   (United States)

^j ASTRAZENECA   (United Kingdom)

^k MEDIMMUNE   (United States)

^l ASTRAZENECA R AND D   (Sweden)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DAPAGLIFLOZIN; HEMOGLOBIN A1C; PLACEBO; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSIDE; GLYCOSYLATED HEMOGLOBIN; INSULIN;

ADULT; ADVERSE OUTCOME; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GENITAL TRACT INFECTION; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; BLOOD; CHEMICALLY INDUCED; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DIABETIC KETOACIDOSIS; DRUG EFFECT; GLUCOSE BLOOD LEVEL; HYPOGLYCEMIA; METABOLISM; MULTICENTER STUDY; TREATMENT OUTCOME;

ADULT; BENZHYDRYL COMPOUNDS; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, TYPE 1; DIABETIC KETOACIDOSIS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GLUCOSIDES; GLYCATED HEMOGLOBIN A; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 85052622868     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc18-0623     Document Type: Article

References (26)

1. McKnight JA, Wild SH, Lamb MJ, et al. Glycaemic control of type 1 diabetes in clinical practice early in the 21st century: an international comparison. Diabet Med 2015; 32:1036-1050
2. Miller KM, Foster NC, Beck RW, et al.; T1D Exchange Clinic Network. Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry. Diabetes Care 2015; 38:971-978
3. Lind M, Svensson AM, Kosiborod M, et al. Glycemic control and excess mortality in type 1 diabetes. N Engl J Med 2014; 371:1972-1982
4. National Institute for Health and Care Excellence. Type 1 diabetes in adults: diagnosis and management [Internet], 2015. Available from https://www.nice.org.uk/guidance/ng17. Accessed 31 January 2018
5. Donnelly LA, Morris AD, Frier BM, et al.; DARTS/MEMO Collaboration. Frequency and predictors of hypoglycaemia in type 1 and insulin-treated type 2 diabetes: a population-based study. Diabet Med 2005; 22:749-755
6. Nathan DM; DCCT/EDIC Research Group. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study at 30 years: overview. Diabetes Care 2014; 37:9-16
7. UK Hypoglycaemia Study Group. Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia 2007; 50:1140-1147
8. Russell-Jones D, Khan R. Insulin-associated weight gain in diabetes-causes, effects and coping strategies. Diabetes Obes Metab 2007; 9:799-812
9. Frier BM, Schernthaner G, Heller SR. Hypoglycemia and cardiovascular risks. Diabetes Care 2011; 34(Suppl. 2):S132-S137
10. Lavie CJ, Milani RV, Ventura HO. Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. J Am Coll Cardiol 2009; 53:1925-1932
11. Kalra S, Mukherjee JJ, Venkataraman S, et al. Hypoglycemia: the neglected complication. Indian J Endocrinol Metab 2013; 17:819-834
12. Harris S, Mamdani M, Galbo-Jørgensen CB, Bøgelund M, Gundgaard J, Groleau D. The effect of hypoglycemia on health-related quality of life: Canadian results from a multinational time trade-off survey. Can J Diabetes 2014; 38:45-52
13. Davis RE, Morrissey M, Peters JR, Wittrup-Jensen K, Kennedy-Martin T, Currie CJ. Impact of hypoglycaemia on quality of life and productivity in type 1 and type 2 diabetes. Curr Med Res Opin 2005; 21:1477-1483
14. Henry RR, Rosenstock J, Edelman S, et al. Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study. Diabetes Care 2015; 38:412-419
15. Chen J, Fan F, Wang JY, et al. The efficacy and safety of SGLT2 inhibitors for adjunctive treatment of type 1 diabetes: a systematic review and meta-analysis. Sci Rep 2017; 7:44128
16. Dandona P, Mathieu C, Phillip M, et al.; DEPICT-1 Investigators. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from amulticentre, double-blind, phase3, randomised controlled trial. Lancet Diabetes Endocrinol 2017; 5:864-876
17. Garg SK, Henry RR, Banks P, et al. Effects of sotagliflozin added to insulin in patients with type 1 diabetes. N Engl J Med 2017; 377:2337-2348
18. Henry RR, Dandona P, Pettus J, Mudaliar S, Xu J, Hansen L. Dapagliflozin in patients with type 1 diabetes: a post hoc analysis of the effect of insulin dose adjustments on 24-hour continuously monitored mean glucose and fasting β-hydroxybutyrate levels in a phase IIa pilot study. Diabetes Obes Metab 2017; 19:814-821
19. Kuhadiya ND, Ghanim H, Mehta A, et al. Dapagliflozin as additional treatment to liraglutide and insulin in patients with type 1 diabetes. J Clin Endocrinol Metab 2016; 101:3506-3515
20. Service FJ, Molnar GD, Rosevear JW, Ackerman E, Gatewood LC, Taylor WF. Mean amplitude of glycemic excursions, a measure of diabetic instability. Diabetes 1970; 19:644-655
21. Seaquist ER, Anderson J, Childs B, et al. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care 2013; 36: 1384-1395
22. Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN. Hyperglycemic crises in adult patients with diabetes. Diabetes Care 2009; 32:1335-1343
23. Dunnett CW, Tamhane AC. A step-up multiple test procedure. J Am Stat Assoc 1992; 87: 162-170
24. Boehringer Ingelheim. Empagliflozin as adjunctive to insulin therapy over 52 weeks in patients with type 1 diabetes mellitus (EASE-2). In: ClinicalTrials.gov [Internet]. Bethesda, MD, National Library of Medicine, 2018. Available from https://clinicaltrials.gov/ct2/show/NCT02414958. NLM Identifier: NCT02414958. Accessed 21 March 2018
25. Boehringer Ingelheim. Empagliflozin as adjunctive to insulin therapy over 26 weeks in patients with T1DM (EASE-3). In: ClinicalTrials.gov [Internet]. Bethesda, MD, National Library of Medicine, 2018. Available from https://clinicaltrials.gov/ct2/show/NCT02580591. NLM Identifier: NCT02580591. Accessed 21 March 2018
26. Henry RR, Thakkar P, Tong C, Polidori D, Alba M. Efficacy and safety of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to insulin in patients with type 1 diabetes. Diabetes Care 2015; 38:2258-2265